Testicular cancer.
Although testicular cancer accounts for only 1 percent of all tumors in males, it is the most common malignancy in males between 15 and 34 years of age. Cryptorchidism is the most significant risk factor for testicular cancer, increasing the risk up to 11-fold. A painless testicular mass is the classic presentation for testicular cancer, although a number of patients present with diffuse pain or swelling. Ultrasonography may be helpful in confirming the presence of a scrotal mass within the testicle. Intratesticular masses are considered malignant until proved otherwise. Radical orchiectomy is the treatment for the primary tumor. Staging of disease is based on tumor histology, serum tumor markers and presence of lymph-node or other metastatic disease. Depending on the stage of disease, further treatment may include observation, radiotherapy, chemotherapy or surgery. Survival rates in patients with testicular cancer have improved dramatically in the past 20 years and now exceed 90 percent overall.
D014408:Biomarkers, Tumor / Q000097:blood; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening; D009367:Neoplasm Staging; D010353:Patient Education as Topic; D011379:Prognosis; D015996:Survival Rate; D013664:Teaching Materials; D013736:Testicular Neoplasms / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D014481:United States / Q000453:epidemiology